Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05029960
EARLY_PHASE1

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

Sponsor: University of Rochester

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2022-05-17

Completion Date

2025-08-31

Last Updated

2024-08-09

Healthy Volunteers

No

Conditions

Interventions

DRUG

Brivaracetam

Dose of 50 mg twice daily for 6 months

Locations (1)

University of Rochester Medical Center

Rochester, New York, United States